Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0IE9L
|
|||
| Drug Name |
M4344
|
|||
| Synonyms |
VX-803; Butanehydrazide; Butyrohydrazide; Butyric acid hydrazide; 3538-65-6; butanehydrazide; Butanohydrazide; Butyrylhydrazine; Butanoic acid, hydrazide; n-Butyric acid hydrazide; butyric hydrazide; butanoic acid hydrazide; FCCCRBDJBTVFSJ-UHFFFAOYSA-N; butyryl hydrazine; Butanohydrazide #; EINECS 222-579-0; N-butanoyl-hydrazine; butryic acid hydrazide; ACMC-1AEKP; AC1L2SBF; AC1Q5PVE; SCHEMBL924945; Mr-I-33; ARONIS010643; SCHEMBL11029887; CTK3J2024; DTXSID70188869; MolPort-000-152-665; BDBM233138; NSC41957; NSC24021; KS-000041YT; ALBB-002745; ZINC1608800; NSC-240
Click to Show/Hide
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [1] | |
| Company |
EMD Serono Rockland, MA; Vertex Pharmaceuticals Boston, MA
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H29F2N9O3
|
|||
| Canonical SMILES |
C1CN(CCC1C(=O)N2CCN(CC2)C3COC3)C4=C(C=NC=C4NC(=O)C5=C6N=CC(=CN6N=C5N)F)F
|
|||
| InChI |
1S/C25H29F2N9O3/c26-16-9-30-23-20(22(28)32-36(23)12-16)24(37)31-19-11-29-10-18(27)21(19)34-3-1-15(2-4-34)25(38)35-7-5-33(6-8-35)17-13-39-14-17/h9-12,15,17H,1-8,13-14H2,(H2,28,32)(H,31,37)
|
|||
| InChIKey |
QAYHKBLKSXWOEO-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Serine/threonine-protein kinase ATR (FRP1) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Fanconi anemia pathway | |||
| Cell cycle | ||||
| p53 signaling pathway | ||||
| HTLV-I infection | ||||
| Panther Pathway | p53 pathway | |||
| p53 pathway feedback loops 2 | ||||
| Pathway Interaction Database | Fanconi anemia pathway | |||
| ATR signaling pathway | ||||
| Signaling events mediated by TCPTP | ||||
| Circadian rhythm pathway | ||||
| BARD1 signaling events | ||||
| p53 pathway | ||||
| Reactome | Meiotic synapsis | |||
| Activation of ATR in response to replication stress | ||||
| Regulation of HSF1-mediated heat shock response | ||||
| HDR through Single Strand Annealing (SSA) | ||||
| Processing of DNA double-strand break ends | ||||
| Presynaptic phase of homologous DNA pairing and strand exchange | ||||
| G2/M DNA damage checkpoint | ||||
| WikiPathways | DNA Damage Response | |||
| Meiotic Synapsis | ||||
| Prostate Cancer | ||||
| Integrated Breast Cancer Pathway | ||||
| Integrated Cancer pathway | ||||
| Cell Cycle | ||||
| Cell Cycle Checkpoints | ||||
| miRNA Regulation of DNA Damage Response | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.